Get notified when RIGL files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Cmo Departure With No Disclosed Reason (new) — The filing does not state whether Rojkjaer's separation was voluntary or provide any context for the departure.
Rigel names Alison Hannah CMO, replacing Lisa Rojkjaer who departed June 25
Filed July 1, 2026 · Period ending June 25, 2026 · ~1 min read
Key Changes
-
high
Lisa Rojkjaer separated from Rigel and ceased serving as Chief Medical Officer effective June 25, 2026. The filing does not disclose whether the departure was voluntary or the reason for separation.
Item 5.02 verify on EDGAR → -
high
Alison Hannah appointed Executive Vice President and Chief Medical Officer effective July 1, 2026. She resigned from the board to take the role and brings 25+ years of pharma development experience, including prior CMO role at CytomX Therapeutics.
Item 5.02 verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MSM 10-Q) is open in full — no account needed.
Partner
Trade RIGL commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jul 6, 2026 · How we verify